Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Synthego, a Bay Area biotech startup that won hundreds of millions of dollars in funding for its gene editing products and ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...